Indications
Therapeutic Asset Ratings
13,145 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Tazemetostat
Ependymoma
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Ewing Sarcoma
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Glioma
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Hepatoblastoma
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Malignant Germ Cell Tumor
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Medulloblastoma
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Neuroblastoma
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Osteosarcoma
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Peripheral Primitive Neuroectodermal Tumor
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Central Nervous System Neoplasm
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Refractory Malignant Neoplasm
National Cancer Institute (NCI)
P2
B
(57)
Tazemetostat
Wilms Tumor
National Cancer Institute (NCI)
P2
B
(57)
tcb008
Acute Myeloid Leukemia
TC Biopharm
P2
B
(57)
tcb008
Myelodysplastic Syndrome
TC Biopharm
P2
B
(57)
Tegodor
Malignant Pancreatic Neoplasm
Ruijin Hospital
P2
B
(57)
Tegodor
Pancreatic Neoplasm
Ruijin Hospital
P2
B
(57)
Tenalisib
Breast Cancer
Rhizen Pharmaceuticals SA
P2
B
(57)
Teonanacatl
Borderline Personality Disorder
University of Chicago
P2
B
(57)
Teonanacatl
Parkinson Disease
Yale University
P2
B
(57)
Tern-501
Metabolic Dysfunction-Associated Steatohepatitis
Terns, Inc.
P2
B
(57)
Tern-601
Obesity Disorder
Terns, Inc.
P2
B
(57)
Tesofensine
Acquired Hypothalamic Obesity
Saniona
P2
B
(57)
Testosterone Cipionate
Hypogonadism
Brigham and Women's Hospital
P2
B
(57)
Testosterone Cipionate
Vertebral Column Disorder
Brigham and Women's Hospital
P2
B
(57)
Testosterone Cipionate
Prostate Adenocarcinoma
University of Washington
P2
B
(57)
Showing 3501 to 3525 of 13,145 assets
Previous
Page 141 of 526
Next